<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205580</url>
  </required_header>
  <id_info>
    <org_study_id>GZWCMC</org_study_id>
    <nct_id>NCT02205580</nct_id>
  </id_info>
  <brief_title>Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children</brief_title>
  <official_title>Comparison of Three Different Rates of Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Coblation Tonsillectomy or Adeno-tonsillectomy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jin Ni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Women and Children's Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pain following tonsillectomy or adeno-tonsillectomy in children is severe and
      sometimes last for days. Sufentanil is used by epidural route for postoperative analgesia in
      children. There are few reports about its use for postoperative analgesia by continuous
      intravenous infusion. Its complications include , hypoxia, sedation, pruritus ,nausea and/or
      vomiting.

      The investigators design this protocol to test efficacy of analgesia of three different rates
      of continuous intravenous sufentanil infusion for postoperative pain management following
      coblation tonsillectomy or adeno-tonsillectomy in children. The investigators also compare
      incidence rate of complications for three groups.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective pain score</measure>
    <time_frame>up to 48 hours after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence rate of hypoxia</measure>
    <time_frame>4h,8h,24h,48h after operation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence rate of pruritus</measure>
    <time_frame>4h,8h,24h,48h after operation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>incidence rate of nausea and/or vomiting</measure>
    <time_frame>4h,8h,24h,48h after operation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>incidence rate of sedation</measure>
    <time_frame>4h,8h,24h,48h after operation</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sleep Breathing Disorders</condition>
  <condition>Tonsillitis</condition>
  <condition>Adenoid Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Sufentanil infusion rate 0.02μg•kg－1•h－1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sufentanil infusion rate 0.02μg•kg－1•h－1 lasted for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil infusion rate 0.03μg•kg－1•h－1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sufentanil infusion rate 0.03μg•kg－1•h－1 lasted for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil infusion rate 0.04μg•kg－1•h－1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sufentanil infusion rate 0.04μg•kg－1•h－1 lasted for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuous intravenous sufentanil 0.02μg•kg－1•h－1 infusion</intervention_name>
    <arm_group_label>Sufentanil infusion rate 0.02μg•kg－1•h－1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuous intravenous sufentanil 0.03μg•kg－1•h－1 infusion</intervention_name>
    <arm_group_label>Sufentanil infusion rate 0.03μg•kg－1•h－1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuous intravenous sufentanil 0.04μg•kg－1•h－1 infusion</intervention_name>
    <arm_group_label>Sufentanil infusion rate 0.04μg•kg－1•h－1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists grade I or II children aged 5-8 years undergoing
             coblation tonsillectomy or adeno-tonsillectomy as in-patient

        Exclusion Criteria:

          -  Children with a history of adverse reaction to opioids, long-term use of opioid
             medications, and history of chronic pain.

          -  Psychiatric illness, kidney failure, hypotension, atrioventricular block, myasthenia
             gravis etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Ni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Women and Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou Women and Children's Medical Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>September 28, 2014</last_update_submitted>
  <last_update_submitted_qc>September 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Women and Children's Medical Center</investigator_affiliation>
    <investigator_full_name>Jin Ni</investigator_full_name>
    <investigator_title>Department of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

